Lista de obras - Soonmyung Paik - Dominio Público Uruguay

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy

artículo científico publicado en 2017

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

artículo científico publicado en 2017

A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS

scientific article published on 08 April 2019

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

artículo científico publicado en 2004

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.

artículo científico publicado en 2015

A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes

artículo científico publicado en 2010

AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencing

artículo científico publicado en 2017

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy

artículo científico publicado en 2016

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

article

Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma

artículo científico

Assays for Gene Amplification

article

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in I

artículo científico publicado en 2017

Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer

scientific article published on 13 November 2018

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer

artículo científico publicado en 2016

Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine

artículo científico publicado en 2015

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.

artículo científico

Clinical trial methods to discover and validate predictive markers for treatment response in cancer

artículo científico publicado en 2003

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.

artículo científico publicado en 2017

Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer

artículo científico publicado en 2017

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

artículo científico publicado en 2013

Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer

scientific article published on 26 May 2020

EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines

artículo científico

Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer

artículo científico publicado en 2017

Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation

artículo científico publicado en 2018

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials

artículo científico publicado en 2011

Gene-expression-based prognostic assays for breast cancer

artículo científico publicado en 2010

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative

artículo científico publicado en 2016

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab

artículo científico publicado en 2018

HER2 status and benefit from adjuvant trastuzumab in breast cancer

scientific article published on 01 March 2008

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

artículo científico publicado en 2015

Is gene array testing to be considered routine now?

artículo científico

Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations

scientific article published in PLoS ONE

Nanomaterials for theranostics: recent advances and future challenges.

artículo científico publicado en 2014

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

artículo científico publicado en 2015

Neoadjuvant trials for discovery and validation of predictive markets—a new NSABP clinical trial paradigm

Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.

artículo científico publicado en 2018

New generation of molecular prognostic and predictive tests for breast cancer

artículo científico publicado en 2007

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

artículo científico publicado en 2014

Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

artículo científico publicado en 2014

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma

artículo científico publicado en 2015

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

artículo científico publicado en 2013

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays

artículo científico publicado en 2009

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype

artículo científico publicado en 2017

Prognostic Tests for Estrogen Receptor–Positive Breast Cancer

artículo científico publicado en 2016

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

artículo científico publicado en 2015

Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT

artículo científico publicado en 2018

Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention ⬇️

artículo científico publicado el 13 de junio de 2013

Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy

artículo científico publicado en 2002

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer

scientific article published on 01 August 2019

Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth.

artículo científico publicado en 2018

Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer

artículo científico publicado en 2005

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.

artículo científico publicado en 2016

Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)

artículo científico publicado en 2017

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

scientific article published on 30 November 2018

Lista de obras de Soonmyung Paik

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.

A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes

AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencing

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma

Assays for Gene Amplification

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in I

Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer

Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.

Clinical trial methods to discover and validate predictive markers for treatment response in cancer

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.

Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer

EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines

Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer

Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials

Gene-expression-based prognostic assays for breast cancer

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab

HER2 status and benefit from adjuvant trastuzumab in breast cancer

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

Is gene array testing to be considered routine now?

Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations

Nanomaterials for theranostics: recent advances and future challenges.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

Neoadjuvant trials for discovery and validation of predictive markets—a new NSABP clinical trial paradigm

Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.

New generation of molecular prognostic and predictive tests for breast cancer

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype

Prognostic Tests for Estrogen Receptor–Positive Breast Cancer

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT

Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention ⬇️

Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer

Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth.

Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.

Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial